Gunizi OC, Elpek GO. Protein tyrosine phosphatase nonreceptor 2: A New biomarker for digestive tract cancers. World J Gastrointest Oncol 2025; 17(2): 100546 [PMID: PMC11756013 DOI: 10.4251/wjgo.v17.i2.100546]
Corresponding Author of This Article
Gulsum Ozlem Elpek, MD, Professor, Department of Pathology, Akdeniz University Medical School, Dumlupinar Bulvarı, Antalya 07070, Türkiye. elpek@akdeniz.edu.tr
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100546 Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100546
Protein tyrosine phosphatase nonreceptor 2: A New biomarker for digestive tract cancers
Ozlem Ceren Gunizi, Gulsum Ozlem Elpek
Ozlem Ceren Gunizi, Gulsum Ozlem Elpek, Department of Pathology, Akdeniz University Medical School, Antalya 07070, Türkiye
Author contributions: Gunizi OC and Elpek GO were involved in data curation, designing and performing the research, and writing the paper.
Conflict-of-interest statement: The authors declare there is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gulsum Ozlem Elpek, MD, Professor, Department of Pathology, Akdeniz University Medical School, Dumlupinar Bulvarı, Antalya 07070, Türkiye. elpek@akdeniz.edu.tr
Received: August 19, 2024 Revised: November 2, 2024 Accepted: November 20, 2024 Published online: February 15, 2025 Processing time: 151 Days and 20.5 Hours
Core Tip
Core Tip: Protein tyrosine phosphatase nonreceptor 2 (PTPN2) is a member of the protein tyrosine phosphatase family of signaling proteins. Numerous studies have examined the roles of this molecule in antitumor immunity and therapy because of its significant effects on a wide range of events, including the production and distribution of immune cells and numerous pathways that are important to the behavior and treatment of cancers. The role of PTPN2 in gastrointestinal (GI) cancers has been investigated in a limited number of studies, indicating that PTPN2 has heterogeneous effects on different tumors and even on the same type of GI cancer. Currently, this situation limits the recommendation of PTPN2 as a potential biomarker for predicting cancer prognosis and the efficacy of immunotherapy necessitates further studies in GI tumors.
